Bevacizumab and Radiation Therapy for Sarcomas - Full Text View

Purpose

The main purpose of this study is to test the effectiveness of bevacizumab in combination with radiation therapy to see what effects (good or bad) they have on patients with soft tissue sarcoma. Bevacizumab is an antibody designed specifically to slow or stop the growth of cancerous tumors by decreasing the blood supply to the tumor. Bevacizumab is approved by the FDA in combination with intravenous 5-fluorouracil-based chemotherapy as a treatment for patients with cancer of the colon or rectum that has spread. However, the use of bevacizumab in combination with radiation for sarcomas is still under investigation.

Condition	Intervention	Phase
Soft Tissue Sarcoma Fibrous Histiocytoma Liposarcoma Leiomyosarcoma Fibrosarcoma Synovial Sarcoma	Drug: Bevacizumab Radiation: Radiation Therapy Procedure: Surgery	Phase 2


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: No masking Primary Purpose: Treatment
Official Title:	A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas

Resource links provided by NLM:

MedlinePlus related topics: Soft Tissue Sarcoma

Drug Information available for: Bevacizumab

Genetic and Rare Diseases Information Center resources: Soft Tissue Sarcoma Liposarcoma Leiomyosarcoma Synovial Sarcoma Fibrosarcoma

U.S. FDA Resources

Further study details as provided by Yen-Lin Evelyn Chen, MD, Massachusetts General Hospital:

Primary Outcome Measures:

Objective Response Rate for Neoadjuvant Bevacizumab Combined With Radiation Therapy for Intermediate and High-risk Soft Tissue Sarcomas. [ Time Frame: 3 years ]
The count of participants with greater than or equal to 80% pathological necrosis in the resected specimen following neoadjuvant bevacizumab and radiation.

Secondary Outcome Measures:

Change in Median Microvessel Density (MVD) After Bevacizumab Alone [ Time Frame: baseline and 3 years ]
The percentage change in median microvessel density (MVD) after Bevacizumab treatment alone
Average Change in Blood Flow, Blood Volume,and Permeability Surface Area [ Time Frame: 3 years ]
The percentage reduction in blood flow, blood volume,and permeability surface area of the tumor following combination therapy as determined by perfusion CT (computerized tomography) scan. The percent change represents the combined average percent change for flow, volume, and permeability together.
Local Control Rate [ Time Frame: 3 years ]
The number of patients with local recurrence after a median follow-up of 24 months. Local recurrence is defined as disease progression (new cancer growth) at the primary cancer site.
Distant Recurrence [ Time Frame: 3 years ]
The number of participants with distant recurrence at the time of last follow-up. Distant recurrence is when cancer has spread (metastasized) to areas farther away from where the primary cancer site is.
Disease Free Survival [ Time Frame: 3 years ]
The median amount of time from the end of treatment until to distant recurrence. Distant recurrence is when cancer spreads to areas in the body away from the primary cancer site.


Enrollment:	20
Study Start Date:	July 2006
Study Completion Date:	March 2010
Primary Completion Date:	March 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Bevacizumab, Radiation, and Surgery Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)	Drug: Bevacizumab Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses Other Name: Avastin Radiation: Radiation Therapy External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good. Procedure: Surgery Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.

Arms

Assigned Interventions

Experimental: Bevacizumab, Radiation, and Surgery

Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)

Drug: Bevacizumab

Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses

Other Name: Avastin

Radiation: Radiation Therapy

External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.

Procedure: Surgery

Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.

Detailed Description:

The dose of bevacizumab and radiation therapy will be the same for all participants throughout the study.
Bevacizumab will be given as an intravenous infusion every 2 weeks for a total of 4 doses.
Radiation therapy will begin 2 weeks after the first bevacizumab infusion and will be delivered 5 days per week over a period of 6 weeks. This is done as an outpatient procedure. Each 2 week period will be considered a separate treatment cycle. Participants will be treated with radiation therapy for a maximum of 3 cycles (6 weeks).
A surgeon will evaluate the participants tumor by radiologic studies before study treatment to determine if surgical removal is possible. After the completion of study treatment, a surgeon will repeat the evaluation of the tumor. Surgery will performed 6-7 weeks after the completion of radiation therapy.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Primary soft tissue sarcoma (STS) or an isolated local recurrence of STS. Open incisional biopsy or core biopsies should be performed within 8 weeks prior to registration
Tumor grade of intermediate or high grade
Tumor must be located on the upper extremity, the lower extremity, trunk, retroperitoneum, or pelvis
Primary tumors must be > 5.0cm in maximal diameter and local recurrence can be any size
18 years of age or older
Zubrod performance status of 0-2
Adequate organ and marrow function

Exclusion Criteria:

Metastatic disease
Pregnant or lactating women
HIV positive patients
Prior treatment with radiation, chemotherapy or biotherapy for this tumor
History or evidence of central nervous system (CNS) disease
Serious, non-healing wound, ulcer, or bone fracture
Clinically significant cardiovascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or Grade II or greater peripheral vascular disease within 1 year
History of stroke within the past 6 months
Major surgical procedure or significant traumatic injury within 28 days
Current or recent (within 10 days) use of full-dose oral or parenteral anticoagulants or thrombolytic agents.
Presence of bleeding diathesis or coagulopathy
Proteinuria at baseline or clinically significant impairment of renal function
History of abdominal fistula, gastrointestinal perforation, or inta-abdominal abscess within the past 6 months
Documented history of uncontrolled seizures
Grade 2 or greater sensory neuropathy based upon the NCI CTCAE, version 3.0
Known history of deep vein thrombosis or pulmonary embolus
Known hypercoagulable disorder
History of hepatic cirrhosis or current hepatic dysfunction

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00356031

Locations


United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114

Sponsors and Collaborators

Massachusetts General Hospital

National Institutes of Health (NIH)

National Cancer Institute (NCI)

Investigators


Principal Investigator:	Yen-Lin Chen, MD	Massachusetts General Hospital

More Information

Publications:

Yoon SS, Duda DG, Karl DL, Kim TM, Kambadakone AR, Chen YL, Rothrock C, Rosenberg AE, Nielsen GP, Kirsch DG, Choy E, Harmon DC, Hornicek FJ, Dreyfuss J, Ancukiewicz M, Sahani DV, Park PJ, Jain RK, Delaney TF. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1081-90. doi: 10.1016/j.ijrobp.2010.07.024. Epub 2010 Oct 6.


Responsible Party:	Yen-Lin Evelyn Chen, MD, Study Principal Investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00356031 History of Changes
Other Study ID Numbers:	05-090 1R21CA117128-01A1 ( U.S. NIH Grant/Contract )
Study First Received:	July 21, 2006
Results First Received:	February 16, 2017
Last Updated:	April 14, 2017

Keywords provided by Yen-Lin Evelyn Chen, MD, Massachusetts General Hospital:


Avastin

Additional relevant MeSH terms:


Sarcoma Leiomyosarcoma Liposarcoma Sarcoma, Synovial Fibrosarcoma Histiocytoma Histiocytoma, Benign Fibrous Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Neoplasms, Muscle Tissue	Neoplasms, Adipose Tissue Neoplasms, Connective Tissue Neoplasms, Fibrous Tissue Bevacizumab Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents

ClinicalTrials.gov processed this record on July 21, 2017